References - Therapeutic Strategies in Cancer Biology and Pathology - page 220

Kawada, M., Usami, I., Someno, T., Watanabe, T., Abe, H., Inoue, H., et al., 2010.
NBRI17671, a new antitumor compound, produced by Acremonium sp CR17671. J.
Antibiot. 63, 237-243.
Kawai, K., Yamaga, M., Iwamae, Y., Kiyota, M., Kamata, H., Hirata, H., et al., 2004. A PLC
delta(1)-binding protein, p122RhoGAP, is localized in focal adhesions. Biochem. Soc.
Trans. 32, 1107-1109.
Kawatani, M., Okumura, H., Honda, K., Kanoh, N., Muroi, M., Dohmae, N., et al., 2008. The
identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I.
Proc. Natl. Acad. Sci. U.S.A. 105, 11691-11696.
Kelleher, F.C., 2011. Hedgehog signaling and therapeutics in pancreatic cancer.
Carcinogenesis 32, 445-451.
Keller, E.T., 2004. Metastasis suppressor genes: a role for raf kinase inhibitor protein (RKIP).
Anti-cancer Drugs 15, 663-669.
Ketola, K., Hilvo, M., Hyotylainen, T., Vuoristo, A., Ruskeepaa, A.L., Oresic, M., et al., 2012.
Salinomycin inhibits prostate cancer growth and migration via induction of oxidative
stress. Br. J. Cancer 106, 99-106.
Khanim, F.L., Merrick, B.A.M.E., Giles, H.V., Jankute, M., Jackson, J.B., Giles, L.J., et al.,
2011. Redeployment-based drug screening identifies the anti-helminthic niclosamide as
anti-myeloma therapy that also reduces free light chain production. Blood Cancer J. 1, e39.
Kikuchi, S., Yamada, D., Fukami, T., Masuda, M., Sakurai-Yageta, M., Williams, Y.N., et al.,
2005. Promoter methylation of DAL-1/4.1B predicts poor prognosis in non-small cell
lung cancer. Clin. Cancer Res. 11, 2954-2961.
Kilinc, D., Ozdemir, O., Ozdemir, S., Korgali, E., Koksal, B., Uslu, A., et al., 2012. Alterations
in promoter methylation status of tumor suppressor HIC1, SFRP2, and DAPK1 genes in
prostate carcinomas. DNA Cell. Biol. 31, 826-832.
Kim, H.J., Hong, J.M., Yoon, K.A., Kim, N., Cho, D.W., Choi, J.Y., Lee, I.K., Kim, S.Y.
2012c. Early growth response 2 negatively modulates osteoclast differentiation through
upregulation of Id helix-loop-helix proteins. Bone 51, 643-650.
Kim, H.L., Vander Griend, D.J., Yang, X., Benson, D.A., Dubauskas, Z., Yoshida, B.A., et al.,
2001. Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression
is inversely related to histological pattern in advancing human prostatic cancers. Cancer
Res. 61 2833-1837
Kim, H.S., Kim, G.Y., Lim, S.J., Kim, Y.W., 2010. Loss of Raf-1 kinase inhibitory protein in
pancreatic ductal adenocarcinoma. Pathology 42, 655-660.
Kim, H.S., Park, S.J., Lee, K.Y., Park, Y.K., Kim, Y.W., 2012a. Reduced Raf-1 kinase inhibi-
tor protein expression predicts less favorable outcomes in patients with hepatic colorectal
metastasis. Oncol. Rep. 28, 161-171.
Kim, K.H., Back, J.H., Zhu, Y., Arbesman, J., Athar, M., Kopelovich, L., et al., 2011.
Resveratrol targets transforming growth factor-beta 2 signaling to block UV-induced
tumor progression. J. Invest. Dermatol. 131, 195-202.
Kim, S.A., Choi, H.C., 2012. Metformin inhibits inflammatory response via AMPK-PTEN
pathway in vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 425,
866-872.
Kim, T.Y., Lee, J.W., Kim, H.P., Jong, H.S., Kim, T.Y., Jung, M., et al., 2007. DLC-1, a
GTPase-activating protein for Rho, is associated with cell proliferation, morphology, and
migration in human hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 355,
72-77.
Kim, V.N., 2005. MicroRNA biogenesis: coordinated cropping and dicing. Nat. Rev. Mol.
Cell. Biol. 6, 376-385.